Hadasit, the Innovation Engine of Hadassah Medical Organization and BIRAD, the Commercialization arm of Bar-Ilan University announced today that they have entered into the research and license agreement with Immix BioPharma, for the development and commercialization of novel tissue specific therapeutics based on anti-BCMA CAR-T cells targeting plasma cell. This technology has been developed as the result of a collaboration between Prof. Polina Stepensky, of Hadassah Medical Center, Jerusalem and Prof. Cyrille J. Cohen, of Bar-Ilan University, Ramat Gan. Dr. Shlomit Kfir-Erenfeld and Dr. Nathalie Asherie, of Hadassah Medical Center, and Ortal Harush, of Bar-Ilan University, also participated in the research. For more information visit Yahoo! Finance